Lumvoa (veligrotug-vvze) approved for thyroid eye disease (Jun 25 2026) — Viridian’s first approval
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/13/26) through T+5. Run-up high $33.78 on 1/21/26, low $13.3 on 5/1/26 (T-120 to T-1). FDA decision 6/30/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-30
OutcomeApproved
Drug / candidateVeligrotug (VRDN-001) - (THRIVE-2)
IndicationThyroid Eye Disease (TED)
CompanyViridian Therapeutics
Market-cap tierSmall
120-day run-up (T-120→T-1)-38.8%
Cohort decision-day move (history)±3% median
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction.